Actelion Pharmaceuticals Ltd

Overview

Actelion Pharmaceuticals Ltd (Actelion), a subsidiary of Johnson & Johnson, is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost) and Uptravi (selexipag). Its specialty product includes Zavesca (miglustat). Actelion also offers approved treatments for diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, multiple sclerosis and digital ulcers in patients with systemic sclerosis. The company offers its products in various countries across Europe, besides Japan, China, Russia and the US, among others. Actelion is headquartered in Allschwil, Switzerland.
Key Stats
Address
Gewerbestrasse 16, Allschwil, Basel-Landschaft
Headquarters

Switzerland

Contact

41 61 5656565

Industry

Pharmaceuticals and Healthcare

Peer Comparison

Key Parameters Actelion Pharmaceuticals LtdF. Hoffmann-La Roche LtdSanthera Pharmaceuticals Holding AGMymetics Corp
Key Information
Headquarters Switzerland Switzerland Switzerland Switzerland
Headquarter City Allschwil BASEL PRATTELN EPALINGES
Headquarter State/Province Basel-Landschaft - - -
No. of Employees - 101,465 86 8
Entity Type Private Public Public Public

Products & Services

Actelion focuses on the discovery, development and commercialization of innovative treatments. The company’s key products and brands include the following:

Products
  • Tracleer (bosentan)
  • Ventavis (iloprost)
  • Veletri (epoprostenol for injection)
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Tracleer
  • Ventavis
  • Veletri
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit

Employees

Name Position Board Since Age Biography
Andre C. Muller Chief Financial Officer; Executive Vice President Senior Management 2013 55 Mr. Andre C. Muller has been the Chief Financial Officer and Executive Vice President of Actelion since 2013. Prior to...
Nicholas Franco Executive Vice President; Chief Business Development Officer Senior Management 2011 57 Mr. Nicholas Franco has been the Chief Business Development Officer and Executive Vice President of Actelion since 2011. Prior to...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In March, the company entered into an agreement with Beyond Batten Disease Foundation to provide…
2019 Contracts/Agreements In March, Actelion collaborated with Third Pole Therapeutics to expand access to the latter's iNO…
2019 Contracts/Agreements In May, Actelion and Owlstone Medical signed a strategic partnership to discover and validate a…
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Actelion Pharma Schweiz AG

Address

Stadtturmstrasse 5, Baden
Switzerland

Telephone

41 56 2002940

Website

www.actelion.ch
Actelion Pharmaceuticals France SAS

Address

21 Bd de la Madeleine, Paris
France

Telephone

33 1 58623232

Website

www.actelion.fr
CoTherix Inc

Address

Suite 101, 5000 Shoreline Court, San Francisco
United States of America

Telephone

1 650 8086500

Actelion Pharma Polska Sp. z.o.o.

Address

ul. Nowogrodzka 21, Warsaw
Poland

Telephone

48222623100

Actelion Pharmaceuticals Hellas S.A.

Address

6-8 Agisilaou str., Blue Land Center, gios Thomas Maroussi, Athens
Greece

Telephone

30 210 6752500

Actelion Pharmaceuticals Austria GmbH

Address

Bosendorferstraße 4, Top 23, Wien
Austria

Telephone

43 1 5054527

Website

www.actelion.com
Actelion Clinical Research, Inc.

Address

1820 Chapel Avenue West, Suite 300, Cherry Hill
United States of America

Telephone

1 856 7734300

Actelion Pharmaceuticals Canada Inc

Address

2550 Daniel-Johnson Boulevard, Suite 701, Laval
Canada

Telephone

1 450 6811664

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
02 Mar 2021 Beyond Batten Disease Foundation Enters into Agreement with Actelion Pharma Partnership Actelion Pharmaceuticals Ltd; Beyond Batten Disease Foundation
06 Mar 2020 Actelion Pharmaceuticals Ltd Enters Phase I Clinical Trial Agreement with Simbec-Orion Group Ltd for cenerimod (GDCT0308247) Contract Service Agreement Actelion Pharmaceuticals Ltd; Actelion Pharmaceuticals Ltd IQVIA Holdings Inc; Simbec-Orion Group Ltd
20 May 2019 Owlstone Medical Enters into Collaboration with Actelion Pharma Partnership Actelion Pharmaceuticals Ltd; Owlstone Medical Ltd
11 Apr 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
26 Mar 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
11 Dec 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit